BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $799M
1-Year Return 36.47%
This Quarter Return
+41.34%
1 Year Return
+36.47%
3 Year Return
+278.05%
5 Year Return
+363.53%
10 Year Return
–
AUM
$1.59B
AUM Growth
+$520M
Cap. Flow
+$280M
Cap. Flow %
17.58%
Top 10 Hldgs %
83.78%
Holding
29
New
7
Increased
2
Reduced
3
Closed
3

Top Buys

1
AVIR icon
Atea Pharmaceuticals
AVIR
+$235M
2
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$62.8M
3
CCCC icon
C4 Therapeutics
CCCC
+$54.4M
4
SLDB icon
Solid Biosciences
SLDB
+$24.2M
5
APTX
Aptinyx Inc. Common Stock
APTX
+$11.5M

Top Sells

1
REPL icon
Replimune Group
REPL
+$48.9M
2
SAGE
Sage Therapeutics
SAGE
+$30.5M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$22M
4
KYMR icon
Kymera Therapeutics
KYMR
+$15.5M
5
PANA.U
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
+$5M

Sector Composition

1 Healthcare 93.91%
2 Financials 0.53%
Name Market Value Portfolio Weight Shares or Principal Shares
Change % 		Capital Flow
MLTX icon
26
MoonLake Immunotherapeutics
MLTX
$3.34B
$2.84M 0.18%
+250,000
New +$2.84M
REPL icon
27
Replimune Group
REPL
$447M
– –
-2,122,415
Closed -$48.9M
SAGE
28
DELISTED
Sage Therapeutics
SAGE
– –
-499,100
Closed -$30.5M
PANA.U
29
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
– –
-500,000
Closed -$5M
1
2